Skip to content
OpenCapital
Get started

Eli Lilly LLY Other oncology — Revenue

Other product segments

Mounjaro
$8.66B+125%
Zepbound
$4.16B+79.9%
Verzenio
$1.3B+12.3%
Jardiance
$1.11B+9.9%
Trulicity
$919M-16.1%
Other cardiometabolic health
$905M-4.2%
Taltz
$733M-3.8%
Other immunology
$470M+44.2%
Neuroscience
$382M+40.4%

Similar metrics at other companies

Pfizer logo
PFEAll other Oncology — Revenues:
$376M-0.3%
BillionToOne, Inc. logo
BLLNOncology — Revenue
$10.72M+392%
Johnson & Johnson logo
JNJOther Oncology — Sales to customers (Note 9)
$192M-10.3%
Jazz Pharmaceuticals logo
JAZZOncology — Revenue from Contract with Customer, Excluding Assessed Tax
$333.4M+45.3%
Arcus Biosciences logo
RCUSOther — Total revenues
$2M—
Natera, Inc. logo
NTRAOncology — Revenue recognized
$100K0.0%

Other financials

Income statement

See full
Revenue$19.8B+55.5%
Gross profit$16.2B+54.4%
Net income$7.4B+168%
EPS (diluted)$8.26+170%

Balance sheet

See full
Cash & equivalents$5.3B+70.8%
Total debt$43.4B+12.6%
Total equity$31.2B+97.9%
Total assets$116.58B+30.4%

Cash flow

See full
Operating cash flow$5.3B+220%
CapEx$2.3B+54.0%
Free cash flow$3.0B+1,828%

Valuation

See full
Market cap$1.09T+56.4%
Enterprise value$1.12T+53.8%
P/E42.9×-7.3×
P/S15×+2.0×

Profitability

See full
Gross margin82.8%+1.1pp
Net margin35%+12.3pp
FCF margin16.4%+8.7pp

Returns & leverage

See full
Return on equity107.6%+29.9pp
Debt / equity1.4×-1.1×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's other oncology — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Eli Lilly's other oncology — revenue?
Eli Lilly (LLY) reported other oncology — revenue of $966M in Q1 2026.
How has Eli Lilly's other oncology — revenue changed year-over-year?
Eli Lilly's other oncology — revenue increased by 22.4% year-over-year, from $789M to $966M.
What is the long-term trend for Eli Lilly's other oncology — revenue?
Over 4 years (2021 to 2025), Eli Lilly's other oncology — revenue has grown at a 82.3% compound annual growth rate (CAGR), from $330.5M to $3.65B.
What does other oncology — revenue mean?
This metric represents the total net sales generated from the company's oncology product portfolio excluding its primary flagship cancer therapies. It captures the revenue contribution from secondary or emerging oncology assets that are critical for diversifying the firm's cancer treatment pipeline. Monitoring this segment helps investors assess the commercial traction of smaller-scale or newer therapeutic agents within the broader oncology business unit.